Smart scans guide radiation to zap rectal cancer more precisely

NCT ID NCT05108428

Ongoing Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether using MRI scans during radiation treatment can help doctors adjust the radiation dose to better target rectal cancer. Twenty people with stage II or III rectal cancer will receive standard chemotherapy plus MRI-guided radiation. The main goal is to see if this personalized approach is feasible and leads to complete tumor disappearance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Capecitabine, FOLFOX regimen, and MRI-guided radiation therapy
What this could lead to: If successful, this approach could increase the chance of eliminating all detectable tumor after treatment, potentially reducing the need for more aggressive surgery.
What could go wrong: This is a very early, small trial (20 people) focused on feasibility, not proof of effectiveness. The approach may not improve outcomes and carries standard risks of chemoradiation like fatigue, nausea, and bowel issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECTAL ADENOCARCINOMA

Contacts and locations

Locations

Moffitt Cancer Center

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.